WO2006001344A1 - Isosorbide-containing jelly preparation - Google Patents
Isosorbide-containing jelly preparation Download PDFInfo
- Publication number
- WO2006001344A1 WO2006001344A1 PCT/JP2005/011555 JP2005011555W WO2006001344A1 WO 2006001344 A1 WO2006001344 A1 WO 2006001344A1 JP 2005011555 W JP2005011555 W JP 2005011555W WO 2006001344 A1 WO2006001344 A1 WO 2006001344A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- isosorbide
- agar
- added
- jelly
- jelly preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Definitions
- the present invention is an invention in the field of pharmaceuticals, and relates to a device for isosorbide preparation that is hard to take and difficult to take.
- Isosorbide is a therapeutic drug for Meniere, which is rapidly absorbed by the gastrointestinal tract, but is not metabolized in the body, thus increasing serum osmotic pressure. As a result, this drug exhibits diuretic action, brain pressure lowering action, intraocular pressure lowering action and endolymphatic pressure lowering action. Isosorbide also has seizures such as dizziness, which is a symptom of Meyerre's disease, and is often taken as a forceful dose, so its medicinal effect needs to appear immediately after taking it. In general, drugs are effective when dissolved and absorbed in the gastrointestinal tract after taking the drug. Therefore, in order for isosorbide to express its effect quickly, it must be dissolved quickly in the gastrointestinal tract. Internal medicines are commercialized as pharmaceuticals based on isosorbide. The reason why the liquid agent is selected as a dosage form is that the liquid agent is already in a dissolved state, so that it can be expected to quickly exhibit a medicinal effect.
- this drug is characterized by being very bitter.
- bitterness reduction by adding sweeteners and the like is being promoted, but the effect is not sufficient.
- 21g to 28g of isosorbide having a bitter taste at a time, so that the concentration of isosorbide in the liquid is reduced to 70w / w with the aim of minimizing the amount of liquid taken by the patient at a time.
- bitterness is reduced by applying sugar coating or film coating.
- various powders, fine granules, and granules containing bitter ingredients are reduced in bitterness by applying film coating in the same manner as tablets or by adding sweeteners such as sucrose.
- a method of containing a bitter component in an insoluble base to suppress dissolution in the oral cavity JP 54-95719, JP 63-303928, JP 2-288821, JP 4-187629, JP 4 -327528, JP-A-6-501027, etc.
- a method of adding a protein-lipid complex as an additive to reduce bitterness JP-A-6-316 537
- a method of blending essential oil or an essential oil component JP-A-5-255126
- a method of adding acidic phospholipid or its lyso form JP-A-7-67552
- a method of adding cacao powder JP-A 2000-95710 and the like are disclosed.
- Patent Document 1 Japanese Patent Laid-Open No. 54-95719
- Patent Document 2 JP-A 63-303928
- Patent Document 3 JP-A-2-88821
- Patent Document 4 JP-A-4-187629
- Patent Document 5 JP-A-4-327528
- Patent Document 6 JP-A-6-501027
- Patent Document 7 JP-A-6-316537
- Patent Document 8 JP-A-5-255126
- Patent Document 9 JP-A-7-67552
- Patent Document 10 JP 2000-95710 A
- Patent Document 11 JP 2001-226293 A
- isosorbide liquid which is a therapeutic agent for Meniere's disease, has a strong bitter taste and is strongly desired to improve its ingestibility.
- an isosorbide preparation with good ingestibility has not been achieved yet. Accordingly, it is an object to provide an isosorbide preparation with improved dosing ability without impairing the characteristics of rapid and powerful drug efficacy required for an isosorbide preparation.
- the present inventors diligently studied for the purpose of improving the dosage of an isosorbide solution that is bitter and difficult to drink.
- the elution of isosorbide with this jelly formulation was significantly slower than that of the liquid, as was feared that the effect of improving the dosage of isosorbide by jelly formation was observed. This was thought to be due to the suppression of elution of isosorbide, which is a bitter component, by gelling.
- the present inventors conducted further diligent investigations, and surprisingly, by using agar as a gelling agent, isosorbide can be quickly dissolved in the jelly formulation as well as the liquid, and the ingestion can be improved. I found it. Furthermore, as a result of adding cacao powder to improve the bitterness, it was found that the bitterness is reduced synergistically and it is easy to take large changes. Based on this knowledge, the inventors have completed the present invention.
- the present invention is an isosorbide-containing jelly preparation characterized by containing isosorbide and agar.
- the preparation of the present invention preferably further contains cacao powder.
- the amount of agar added is preferably 0.3-2 w / w% of the total jelly preparation.
- the present invention also provides a method for producing an isosorbide-containing jelly preparation. That is, the method of the present invention is a method for producing an isosorbide-containing jelly preparation characterized in that at least agar, isosorbide and water are mixed, dissolved by heating and then cooled to room temperature or lower. Here, it is preferable to add and mix cacao powder together with agar, isosorbide and water. The invention's effect
- the patient can take it without worrying about the strong bitter taste of isosorbide, and it can be expected to improve the compliance.
- the preparation of the present invention is rapidly isolated in the gastrointestinal tract in the same manner as an internal solution. Since the drug is eluted, the medicinal effects are rapidly developed in the same manner as the internal solution.
- the concentration of isosorbide contained in the preparation of the present invention is not particularly limited, but is preferably 50 to 80 w / w%. This is because it is natural that the bitterness is alleviated if the content of isosorbide in a certain amount of jelly preparation is reduced. Since the single dose of isosorbide is very high, 21g to 28g, When the content of isosorbide is low, it is necessary to take a large amount of jelly at a time, which makes it difficult to take isosorbide.
- isosorbide shows rapid elution as in the case of liquids, so that it can be expected that the drug will be rapidly taken or a powerful drug effect will be exhibited.
- rapid and powerful dissolution means that, in the Japanese Pharmacopoeia dissolution test method, the dissolution of isosorbide from the jelly preparation after 15 minutes is 85% or more. Isosorbide elutes quickly even in the digestive tract, and immediately develops a medicinal effect in the same way as a solution.
- the agar used in the present invention is a polysaccharide having galactose as a basic skeleton, and has different molecular weights and functional groups depending on the origin and production method of seaweed as a raw material, so that its characteristics are also different. Accordingly, the amount of addition cannot be generally defined, but is preferably 0.3 to 2 w / w%, more preferably 0.5 to 1.5 w / w% with respect to the total weight of the jelly preparation. When the amount of agar used is less than the above range, the elution of isosorbide from the jelly preparation is not affected, but the strength of the jelly is reduced and the bitterness reduction effect is reduced. Also, it may not gel.
- the amount used is increased, poor agar dissolution may occur, or the viscosity of the liquid before gelation may be very high, making it difficult to fill the container. Furthermore, the jelly becomes too hard and the feeling of administration becomes worse, and the elution of isosorbide, which is a jelly preparation, is delayed. Therefore, the amount of agar is preferably within the above range in order to improve the feeling of taking by reducing the bitter taste of isosorbide and to ensure rapid dissolution of isosorbide from the jelly preparation.
- the gelling agent it is desirable to use agar alone, but other gelling agents can be added.
- Examples of the gelling agent to be added to agar include carrageenan, xanthan gum, low-strength bean gum, and alginate. However, a lot of these Doing so should impair the properties of the agar, so the added amount should be small.
- the effect of improving the dosage by reducing the bitter taste of isosorbide of the present invention is enhanced by adding cacao powder.
- the optimal amount is 0.1 to 5 w / w% based on the total weight of the jelly preparation.
- the combination of chocolate flavor and saccharin sodium is most preferable for the bitterness of isosorbide.
- the method for producing the preparation of the present invention is carried out by adding water to agar, isosorbide, cocoa powder, flavor, sweetener as necessary, stirring and dissolving at 90-100 ° C for several minutes, Cool down to the following.
- the order of addition of the additives is not particularly defined.
- it may further contain additives such as a pH adjusting agent, a coloring agent, and a preservative.
- the prepared isosorbide-containing jelly preparation can be stored and packaged in a cup, bag, tube, or the like.
- Example 1 isosorbide + agar + additive
- Example 2 (isosorbide + agar)
- agar 1.2 g was added to about 60 mL of water, and dissolved under heating and stirring at 90 to 100 ° C. for several minutes. Next, 140 g of isosorbide was added little by little, and the mixture was melted and mixed uniformly. Then, the cup was filled and cooled to room temperature.
- Example 4 "isosorbide + (agar + xanthan gum) + additive"
- Example 5 isosorbide + (agar + sodium alginate) + additive
- Example 6 Increase / decrease in the amount of agar
- 0.6 g of agar, 0.24 g of citrate, 0.48 g of anhydrous sodium hydrogen phosphate and 0.6 g of saccharin sodium were added to about 60 mL of water, and the mixture was heated and dissolved at 90-100 ° C for several minutes with stirring.
- 140 g of isosorbide was added and dissolved little by little, and 0.4 g of cacao powder and 0.2 g of chocolate flavor were added and mixed uniformly, filled into a cup and cooled to room temperature.
- Control Example 2 (isosorbide + pectin + additive)
- pectin lg In about 55 mL of water, pectin lg, 4.8 g of citrate and 0.6 g of saccharin sodium were added and dissolved by stirring at 90 to 100 ° C. for several minutes. Next, 140 g of isosorbide was added little by little, and 0.4 g of cacao powder and 0.2 g of chocolate flavor were added and mixed uniformly, filled into a cup and cooled to room temperature.
- Needle illumination example 3 (Isosonolevid + locust bean gum + xanthan gum)
- Needle illumination example 4 (Isosonolevid + Darcomannan + Xanthan gum)
- Control Example 5 (Isosonolevid + locust bean gum + xanthan gum)
- Locust bean gum (1.4 g), xanthan gum (1.4 g), citrate (0.24 g), anhydrous sodium hydrogenphosphate (0.48 g) and saccharin sodium (0.6 g) were added to about 55 mL of water, and dissolved by stirring at 90-100 ° C for several minutes. .
- 140 g of isosorbide was added little by little to dissolve, and 0.4 g of cacao powder and 0.2 g of chocolate flavor were added and mixed uniformly, filled into a cup and cooled to room temperature.
- Control Example 6 (Isosonolevid + dielan gum)
- Example Example 2 and Control Example 1 The feeling of administration of Example Example 2 and Control Example 1 was evaluated by five subjects. Here, the subject put about 5 g of jelly preparation in his mouth and chewed several times for evaluation. In addition, about 5g of the liquid was put in the mouth and evaluated. The evaluation was based on a five-step evaluation, with 1 being no bitterness and 5 being very bitter and difficult to take. The test results are shown in Table 1.
- cacao powder will not be effective unless several tens of percent or even hundreds of percent of the bitter substance is added, but in Example 1, isosorbide, a bitter substance, is contained at a high concentration of 70%. In spite of this, it was confirmed that a small amount of cacao powder showed an excellent bitterness reduction effect due to the synergistic effect of agar and cacao powder.
- Example 6 Six subjects compared the feeling of administration of the jelly preparations of Example 6, Example 7, and Example 8, and examined the effect of the amount of agar added. The subjects put about 5 g of jelly preparation into their mouth and chewed several times for evaluation. Regarding the evaluation of bitterness, since the bitterness of the miscellaneous jelly preparations has also been reduced, it was difficult to set an evaluation standard. Ranking in ascending order of bitterness. In addition, the overall ease of taking was evaluated based on a five-step evaluation, with 1 being very easy to take and 5 being difficult to take. The hardness of the jelly was measured by compressing the jelly at a rate of 60 mm / min using a rheometer with a fixed area plunger and measuring the strength when the jelly breaks. The test results are shown in Table 2, Table 3, and Figure 1.
- Example 6 was relatively less effective in reducing bitterness. The reason for this was thought to be that the gel collapsed in the mouth and the synergistic effect between the agar and cacao powder was weak. Conversely, the gel of Example 8 with a large amount of agar added is very hard as shown in FIG. From the questionnaire results, although the bitterness reduction effect was sufficiently confirmed, the feeling of taking was very bad. In addition, it was considered impossible to mass-produce with very high viscosity during production. Therefore, it is considered that 0.3-2 w / w% is preferred as the amount of the agar supplement, and more preferably 0.5-1.5 w / w%.
- the elution properties of isosorbide having the jelly preparation strength obtained from Example 1 and Control Example 2 to Control Example 6 were tested by the Japanese Pharmacopoeia dissolution test method paddle method. However, water, 900 mL of the Japanese Pharmacopoeia Disintegration Test Method 1 and 2 were used as the test solution, and the paddle rotation speed was 50 rpm.
- the jelly preparation was pulverized into a size of about 2 mm in consideration of mastication. The quantification was performed by the HPLC method.
- a comparison of the dissolution properties of isosorbide with jelly preparations prepared using a jelly preparation using agar and other gelling agents is shown in Figs. 2 to 4, and Fig. 5 shows the results of Example 1 and each control example. The elution rate after minutes was shown together.
- Example 1 which is a jelly preparation using agar as a gelling agent, even if the test solution of water, the first solution, and the second solution is misaligned, isosorbide is rapidly dissolved, It was remarkable that it showed rapid elution independent of the environment.
- the amount of each gelling agent used in each control example is a commonly used amount, and the hardness of the jelly preparation obtained in the control example is the same as or softer than that in Example 1. The test is not a comparison under conditions unfavorable to the control.
- the dissolution test of isosorbide from the jelly preparations of Example 1 and Examples 6 to 8 was performed in the same manner as in Test Example 3. The test results are shown in Figs. From jelly preparations The elution of isosorbide was not greatly affected by the amount of agar added, but the amount added was very large, indicating a slight delay in elution.
- FIG. 1 is a graph showing the relationship between the hardness of an isosorbide-containing jelly preparation and the amount of agar added.
- FIG. 2 is a graph showing the results of an elution test of an isosorbide-containing jelly preparation into the “JP” disintegration test method solution 1 (pH 1).
- FIG. 3 is a graph showing the results of a dissolution test for isosorbide-containing jelly preparations in water.
- FIG. 4 is a graph showing the results of an elution test of an isosorbide-containing jelly preparation into the second solution (pH 6.8) of “JP” disintegration test method.
- FIG. 5 is a graph showing the dissolution rate of an isosorbide-containing jelly preparation after 15 minutes in each dissolution test solution.
- FIG. 6 is a graph showing the effect of adding cacao powder on the dissolution properties of isosorbide-containing jelly preparations.
- FIG. 7 is a graph showing the effect of the amount of agar added on the dissolution properties of an isosorbide-containing jelly preparation into the “JP” disintegration test method solution 1 (pH 1).
- FIG. 8 is a graph showing the effect of the amount of agar added on the dissolution property of isosorbide-containing jelly preparations in water.
- FIG. 9 is a graph showing the effect of the amount of agar added on the dissolution properties of isosorbide-containing jelly preparations into the “JP” disintegration test method solution 2 (pH 6.8).
- FIG. 10 is a graph showing the effect of addition of other gelling agents on the dissolution properties of isosorbide-containing jelly preparations into the “JPA” disintegration test method solution 1 (pH 1).
- FIG. 11 is a graph showing the influence of other gelling agent-added calories on the solubility of isosorbide-containing jelly preparations in water.
- This is a graph showing the effect of addition of other gelling agents on the dissolution properties of jelly preparations containing isosorbide into the “JPA” disintegration test method solution 2 ( PH 6.8).
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
明 細 書 Specification
イソソルビド含有ゼリー製剤 Isosorbide-containing jelly preparation
技術分野 Technical field
[0001] 本発明は、医薬品の分野の発明であり、苦みが強くて服用しにくいイソソルビドの製 剤工夫に関するものである。 [0001] The present invention is an invention in the field of pharmaceuticals, and relates to a device for isosorbide preparation that is hard to take and difficult to take.
背景技術 Background art
[0002] イソソルビドはメニエール治療薬であり、消化管力 速やかに吸収されるが、体内に おいて代謝されないため、血清浸透圧を高める。その結果、本薬物は、利尿作用、 脳圧降下作用、眼圧降下作用、内リンパ圧降下作用を示す。イソソルビドはまた、メ 二エール病の症状であるめまい等の発作が発現して力 頓服として服用することもし ばしばあるため、服用後速やかにその薬効が発現する必要がある。一般に薬物は、 服用後消化管内で溶解し吸収されることにより薬効を発現するため、イソソルビドが 速やかに薬効を発現するためには、消化管内で速やかに溶解する必要がある。イソ ソルビドを主成分とする医薬品としては、内服液剤が商品化されている。液剤が剤形 として選択されて 、る理由として、液剤は既に薬物であるイソソルビドが溶解状態にあ るため、速やかに薬効を発現することが期待できるためである。 [0002] Isosorbide is a therapeutic drug for Meniere, which is rapidly absorbed by the gastrointestinal tract, but is not metabolized in the body, thus increasing serum osmotic pressure. As a result, this drug exhibits diuretic action, brain pressure lowering action, intraocular pressure lowering action and endolymphatic pressure lowering action. Isosorbide also has seizures such as dizziness, which is a symptom of Meyerre's disease, and is often taken as a forceful dose, so its medicinal effect needs to appear immediately after taking it. In general, drugs are effective when dissolved and absorbed in the gastrointestinal tract after taking the drug. Therefore, in order for isosorbide to express its effect quickly, it must be dissolved quickly in the gastrointestinal tract. Internal medicines are commercialized as pharmaceuticals based on isosorbide. The reason why the liquid agent is selected as a dosage form is that the liquid agent is already in a dissolved state, so that it can be expected to quickly exhibit a medicinal effect.
[0003] 一方、この薬物は非常に苦いことが特徴である。そのため、上記液剤においても、 甘味剤等の添カ卩による苦味低減がは力もれてはいるが、その効果は十分なものでは ない。これは、苦味を有するイソソルビドを 1回に 21g〜28gも服用する必要があるため 、患者が 1回に服用する液剤の量を極力少なくすることを目的として、液剤中のイソソ ルビド濃度を 70w/v%程度に高くする必要があるためである。このような理由で、イソソ ルビドの苦味低減は、非常に困難なものとなっている。しカゝも、巿販液剤は、苦み防 止を目的として添加された矯味剤の酸味が強ぐ後苦味が強く現れ、しばしば患者が イソソルビドを服用することを困難としている。従って、イソソルビドの苦味を低減して 服用性を改善することが、医療現場において非常に望まれている。 [0003] On the other hand, this drug is characterized by being very bitter. For this reason, even in the above liquid preparations, bitterness reduction by adding sweeteners and the like is being promoted, but the effect is not sufficient. This is because it is necessary to take 21g to 28g of isosorbide having a bitter taste at a time, so that the concentration of isosorbide in the liquid is reduced to 70w / w with the aim of minimizing the amount of liquid taken by the patient at a time. This is because it needs to be as high as v%. For this reason, it is very difficult to reduce the bitterness of isosorbide. In addition, in the case of potatoes, sales liquids show strong bitterness after the sourness of the flavoring agent added to prevent bitterness and often makes it difficult for patients to take isosorbide. Therefore, reducing the bitter taste of isosorbide and improving the taking ability is highly desired in the medical field.
[0004] イソソルビドのように苦み等の不快な味を示す薬物は多ぐこの不快な味を改善す ることは医薬品の開発において重要な課題であるため、種々の検討がなされている。 例えば、苦み成分を含む錠剤については、糖衣を施したりフィルムコーティングを施 すことにより、苦みの低減が図られている。また、苦み成分を含む各種散剤、細粒剤 、顆粒剤に対しては、錠剤と同様にフィルムコーティングを施すこと、あるいは白糖な どの甘味剤を添加することにより苦みの低減が図られている。さらに、不溶性基剤に 苦み成分を含有させ口腔内での溶出を抑制する方法 (特開昭 54-95719、特開昭 63- 303928、特開平 2-288821、特開平 4-187629、特開平 4-327528、特開平 6-501027等 )、苦みを低減する添加物として蛋白質 脂質複合体を添加する方法 (特開平 6-316 537)、精油または精油成分を配合する方法 (特開平 5-255126)、酸性リン脂質もしくは そのリゾ体を添加する方法 (特開平 7-67552)、カカオ末を添加する方法 (特開 2000- 95710)などが開示されている。これらはいずれも固形製剤に関するものであり、苦味 成分を lg以下程度の少量含むような固形製剤の苦味低減は、これらの方法で比較 的容易に実施することができる。 [0004] Many drugs that exhibit an unpleasant taste such as bitterness such as isosorbide are important issues in the development of pharmaceuticals, and various studies have been made to improve the unpleasant taste. For example, for tablets containing bitter ingredients, bitterness is reduced by applying sugar coating or film coating. In addition, various powders, fine granules, and granules containing bitter ingredients are reduced in bitterness by applying film coating in the same manner as tablets or by adding sweeteners such as sucrose. Further, a method of containing a bitter component in an insoluble base to suppress dissolution in the oral cavity (JP 54-95719, JP 63-303928, JP 2-288821, JP 4-187629, JP 4 -327528, JP-A-6-501027, etc.), a method of adding a protein-lipid complex as an additive to reduce bitterness (JP-A-6-316 537), a method of blending essential oil or an essential oil component (JP-A-5-255126) In addition, a method of adding acidic phospholipid or its lyso form (JP-A-7-67552), a method of adding cacao powder (JP-A 2000-95710) and the like are disclosed. These all relate to solid preparations, and the bitterness reduction of solid preparations containing a small amount of bitterness components of lg or less can be carried out comparatively easily by these methods.
[0005] 一方、液剤の服用性改善の例は、甘味剤を添加するなどの一般的な方法を除くと 、有効な方法は見当たらない。ゼリー化による方法 (特開 2001-226293)も開示されて いるが、この方法では、苦みを示す有効成分の溶出を抑制するため、バイオアベイラ ピリティーが低下したり、薬効の発現が遅くなることが推測される。 [0005] On the other hand, no effective method has been found in examples of improving the ingestibility of liquids, except for general methods such as adding sweeteners. Although a method using jelly (JP-A-2001-226293) is also disclosed, it is estimated that bioavailability will be reduced and the onset of drug efficacy will be delayed in this method in order to suppress the dissolution of active ingredients that show bitterness. Is done.
[0006] 特許文献 1:特開昭 54-95719 [0006] Patent Document 1: Japanese Patent Laid-Open No. 54-95719
特許文献 2:特開昭 63-303928 Patent Document 2: JP-A 63-303928
特許文献 3:特開平 2-288821 Patent Document 3: JP-A-2-88821
特許文献 4:特開平 4-187629 Patent Document 4: JP-A-4-187629
特許文献 5:特開平 4-327528 Patent Document 5: JP-A-4-327528
特許文献 6:特開平 6-501027 Patent Document 6: JP-A-6-501027
特許文献 7:特開平 6-316537 Patent Document 7: JP-A-6-316537
特許文献 8:特開平 5-255126 Patent Document 8: JP-A-5-255126
特許文献 9:特開平 7-67552 Patent Document 9: JP-A-7-67552
特許文献 10:特開 2000-95710 Patent Document 10: JP 2000-95710 A
特許文献 11:特開 2001-226293 Patent Document 11: JP 2001-226293 A
発明の開示 発明が解決しょうとする課題 Disclosure of the invention Problems to be solved by the invention
[0007] メニエール病治療薬であるイソソルビド液剤は、前述のように、苦味が強くその服用 性改善が強く望まれているが、いまだに、服用性のよいイソソルビド製剤はできてい ない。そこで、イソソルビド製剤に必要とされる速や力な薬効発現という特性を損なわ ずに、服用性の改善されたイソソルビド製剤を提供することを課題とする。 [0007] As described above, isosorbide liquid, which is a therapeutic agent for Meniere's disease, has a strong bitter taste and is strongly desired to improve its ingestibility. However, an isosorbide preparation with good ingestibility has not been achieved yet. Accordingly, it is an object to provide an isosorbide preparation with improved dosing ability without impairing the characteristics of rapid and powerful drug efficacy required for an isosorbide preparation.
課題を解決するための手段 Means for solving the problem
[0008] 本発明者らは、苦くて飲みにくいイソソルビド液剤の服用性を改善することを目的と して鋭意検討した。まず、第一に各種のゲル化剤を使用してイソソルビドを含有する ゼリー製剤の調製を試みた。その結果、ゼリー化によりイソソルビドの服用性改善効 果は認められた力 懸念されていたように、このゼリー製剤力ものイソソルビドの溶出 は、液剤より顕著に遅くなることが判明した。これは、ゲルィ匕により苦味成分であるイソ ソルビドの溶出が抑制されたことによると考えられた。そこで本発明者らは、さらに鋭 意検討した結果、驚くことにゲル化剤として寒天を用いることにより、イソソルビドは液 剤と同様にゼリー製剤力 速やかに溶出し、服用性も改善されることを見出した。さら に、苦みを改善するために、カカオ末を添加した結果、苦みは相乗的に低減し、大 変服用し易くなることを見出した。本発明者らは、かかる知見に基づき本発明を完成 するに至った。 [0008] The present inventors diligently studied for the purpose of improving the dosage of an isosorbide solution that is bitter and difficult to drink. First, we tried to prepare a jelly preparation containing isosorbide using various gelling agents. As a result, it was found that the elution of isosorbide with this jelly formulation was significantly slower than that of the liquid, as was feared that the effect of improving the dosage of isosorbide by jelly formation was observed. This was thought to be due to the suppression of elution of isosorbide, which is a bitter component, by gelling. Therefore, the present inventors conducted further diligent investigations, and surprisingly, by using agar as a gelling agent, isosorbide can be quickly dissolved in the jelly formulation as well as the liquid, and the ingestion can be improved. I found it. Furthermore, as a result of adding cacao powder to improve the bitterness, it was found that the bitterness is reduced synergistically and it is easy to take large changes. Based on this knowledge, the inventors have completed the present invention.
[0009] すなわち、本発明は、イソソルビド及び寒天を含むことを特徴とする、イソソルビド含 有ゼリー製剤である。本発明の製剤は、好ましくは、更にカカオ末を含む。また、寒天 の添加量は、ゼリー製剤全体の 0.3〜2w/w%とするのが好ましい。 [0009] That is, the present invention is an isosorbide-containing jelly preparation characterized by containing isosorbide and agar. The preparation of the present invention preferably further contains cacao powder. The amount of agar added is preferably 0.3-2 w / w% of the total jelly preparation.
[0010] 本発明はまた、イソソルビド含有ゼリー製剤の製造方法をも提供する。すなわち、本 発明法は、少なくとも寒天、イソソルビド及び水を混合し、加熱溶解した後、常温以下 に冷却することを特徴とする、イソソルビド含有ゼリー製剤の製造方法である。ここで、 寒天、イソソルビド及び水とともに、更にカカオ末を添加混合することが好ましい。 発明の効果 [0010] The present invention also provides a method for producing an isosorbide-containing jelly preparation. That is, the method of the present invention is a method for producing an isosorbide-containing jelly preparation characterized in that at least agar, isosorbide and water are mixed, dissolved by heating and then cooled to room temperature or lower. Here, it is preferable to add and mix cacao powder together with agar, isosorbide and water. The invention's effect
[0011] 本発明のイソソルビド含有ゼリー製剤を利用することにより、患者はイソソルビドの強 い苦味を気にすることなく服用できるようになり、服薬コンプライアンスの向上が期待 できる。また、本発明の製剤は、内服液剤と同様に消化管内で速やかにイソソルビド を溶出するため、内服液剤と同様に速やかに薬効が発現される。 [0011] By using the isosorbide-containing jelly preparation of the present invention, the patient can take it without worrying about the strong bitter taste of isosorbide, and it can be expected to improve the compliance. In addition, the preparation of the present invention is rapidly isolated in the gastrointestinal tract in the same manner as an internal solution. Since the drug is eluted, the medicinal effects are rapidly developed in the same manner as the internal solution.
発明を実施するための最良の形態 BEST MODE FOR CARRYING OUT THE INVENTION
[0012] 以下、本発明のゼリー製剤について、更に詳細に説明する。 Hereinafter, the jelly preparation of the present invention will be described in more detail.
本発明製剤中のイソソルビドの含有濃度は特に規定されるものではないが、 50〜80 w/w%であることが望ましい。これは、ゼリー製剤一定量中のイソソルビドの含量を少な くすれば、苦味が軽減されるのは当然である力 イソソルビドの 1回服用量は 21g〜28 gと非常に多いため、ゼリー製剤一定量中のイソソルビド含量が少ない場合、 1回に多 量のゼリー製剤を服用することが必要となり、イソソルビドの服用を逆に困難なものと してしまう。 The concentration of isosorbide contained in the preparation of the present invention is not particularly limited, but is preferably 50 to 80 w / w%. This is because it is natural that the bitterness is alleviated if the content of isosorbide in a certain amount of jelly preparation is reduced. Since the single dose of isosorbide is very high, 21g to 28g, When the content of isosorbide is low, it is necessary to take a large amount of jelly at a time, which makes it difficult to take isosorbide.
[0013] 本発明のゼリー製剤から、イソソルビドは液剤と同様に速やかな溶出を示すことから 、服用後速や力な薬効発現が期待できる。ここで速や力な溶出とは、 日本薬局方溶 出試験法において、 15分後のゼリー製剤からのイソソルビドの溶出が 85%以上である ことを意味し、この条件を満たす医薬組成物は、消化管内でも速やかにイソソルビド を溶出し、液剤と同様に直ちに薬効を発現する。 [0013] From the jelly preparation of the present invention, isosorbide shows rapid elution as in the case of liquids, so that it can be expected that the drug will be rapidly taken or a powerful drug effect will be exhibited. Here, rapid and powerful dissolution means that, in the Japanese Pharmacopoeia dissolution test method, the dissolution of isosorbide from the jelly preparation after 15 minutes is 85% or more. Isosorbide elutes quickly even in the digestive tract, and immediately develops a medicinal effect in the same way as a solution.
[0014] 本発明に使用する寒天はガラクトースを基本骨格とする多糖類力 なり、原料であ る海藻の起源や製造方法により分子量や官能基が異なるため、その特性も異なる。 従ってその添加量につ 、ては一概に規定できな 、が、ゼリー製剤全重量に対して 0. 3〜2w/w%がよぐさらに好ましくは 0.5〜1.5 w/w%がよい。寒天の使用量を上記の範 囲より少なくした場合、ゼリー製剤からのイソソルビドの溶出には影響しないが、ゼリ 一強度が低下して苦味の低減効果が少なくなる。また、ゲルィ匕しないこともある。逆に 使用量を増加させた場合には、寒天の溶解不良が生じたり、ゲル化前の液の粘度が 非常に高いため、容器への充填が困難となる場合がある。さらに、ゼリーが固くなりす ぎて服用感が悪くなるとともに、ゼリー製剤力ものイソソルビドの溶出が遅くなる。従つ て、イソソルビドの苦味を低減して服用感を改善しかつゼリー製剤からのイソソルビド の迅速な溶出を確保するには、寒天の量は上記の範囲が好ましい。また、ゲル化剤 としては、寒天を単独で使用することが望ましいが、その他のゲル化剤を添加するこ ともできる。寒天に添加するゲル化剤としては、カラギーナン、キサンタンガム、ロー力 ストビーンガム、アルギン酸塩等を例示することができる。しかし、これらを大量に添カロ することは、寒天の特性を損なうため、添加量は少な目にすべきである。 [0014] The agar used in the present invention is a polysaccharide having galactose as a basic skeleton, and has different molecular weights and functional groups depending on the origin and production method of seaweed as a raw material, so that its characteristics are also different. Accordingly, the amount of addition cannot be generally defined, but is preferably 0.3 to 2 w / w%, more preferably 0.5 to 1.5 w / w% with respect to the total weight of the jelly preparation. When the amount of agar used is less than the above range, the elution of isosorbide from the jelly preparation is not affected, but the strength of the jelly is reduced and the bitterness reduction effect is reduced. Also, it may not gel. Conversely, when the amount used is increased, poor agar dissolution may occur, or the viscosity of the liquid before gelation may be very high, making it difficult to fill the container. Furthermore, the jelly becomes too hard and the feeling of administration becomes worse, and the elution of isosorbide, which is a jelly preparation, is delayed. Therefore, the amount of agar is preferably within the above range in order to improve the feeling of taking by reducing the bitter taste of isosorbide and to ensure rapid dissolution of isosorbide from the jelly preparation. As the gelling agent, it is desirable to use agar alone, but other gelling agents can be added. Examples of the gelling agent to be added to agar include carrageenan, xanthan gum, low-strength bean gum, and alginate. However, a lot of these Doing so should impair the properties of the agar, so the added amount should be small.
[0015] 本発明のイソソルビドの苦味低減による服用性の改善効果は、カカオ末を添加する ことにより増強する。その添加量は、ゼリー製剤全重量に対して 0.1〜5w/w%が最適で ある。さらに必要に応じて、ブドウ糖、果糖、麦芽糖、キシロース、蜂蜜、白糖 (蔗糖)、 水飴、ソルビトール、マン-トール、キシリトール、マルチトール、粉末還元麦芽糖水 飴、ステビア抽出物、アスパルテーム、チョコレートフレーバー、サッカリンナトリウム等 の甘味剤ある 、はコーヒー等の嗜好品あるいは香料を添カ卩してもょ 、。このうちイソソ ルビドの苦みに対して、チョコレートフレーバー、サッカリンナトリウムの組み合わせが 最も好ましい。 [0015] The effect of improving the dosage by reducing the bitter taste of isosorbide of the present invention is enhanced by adding cacao powder. The optimal amount is 0.1 to 5 w / w% based on the total weight of the jelly preparation. In addition, glucose, fructose, maltose, xylose, honey, sucrose (sucrose), starch syrup, sorbitol, mannitol, xylitol, maltitol, powdered reduced maltose starch syrup, stevia extract, aspartame, chocolate flavor, saccharin sodium If you have a sweetener such as coffee, you can add coffee or other luxury products or flavorings. Of these, the combination of chocolate flavor and saccharin sodium is most preferable for the bitterness of isosorbide.
[0016] 本発明製剤の製造方法、即ちゼリー化は、寒天、イソソルビド、必要に応じてカカオ 末、香料、甘味剤に水を加えて、 90〜100°Cで数分間撹拌溶解した後、常温以下に 冷却して行う。ここで、添加物の添加順序は特に規定されない。また、場合により、さ らに pH調整剤、着色剤、保存剤等の添加物を含有することができる。調製されたイソ ソルビド含有ゼリー製剤は、カップ、バッグ、チューブ等に収容、包装することができ る。 [0016] The method for producing the preparation of the present invention, that is, jelly formation, is carried out by adding water to agar, isosorbide, cocoa powder, flavor, sweetener as necessary, stirring and dissolving at 90-100 ° C for several minutes, Cool down to the following. Here, the order of addition of the additives is not particularly defined. In some cases, it may further contain additives such as a pH adjusting agent, a coloring agent, and a preservative. The prepared isosorbide-containing jelly preparation can be stored and packaged in a cup, bag, tube, or the like.
[0017] 以下、実施例及び比較例を挙げて、本発明をさらに詳しく説明する。 Hereinafter, the present invention will be described in more detail with reference to examples and comparative examples.
実施例 Example
[0018] 実施例 1 (イソソルビド +寒天 +添加剤) [0018] Example 1 (isosorbide + agar + additive)
水約 60mLに寒天 1.2g、クェン酸 0.24g、無水リン酸水素ニナトリウム 0.48g及びサッ カリンナトリウム 0.6gを加えて、 90〜100°Cで数分間加熱撹拌溶解した。次にイソソル ビド 140gを少量ずつ加えて溶かし、更にカカオ末 0.4g及びチョコレートフレーバー 0.2 gをカ卩えて均一に混合し、カップに充填して常温まで冷却した。 1.2 g of agar, 0.24 g of citrate, 0.48 g of anhydrous sodium hydrogenphosphate and 0.6 g of saccharin sodium were added to about 60 mL of water, and the mixture was stirred and dissolved at 90-100 ° C for several minutes. Next, 140 g of isosorbide was added and dissolved little by little, and 0.4 g of cacao powder and 0.2 g of chocolate flavor were added and mixed uniformly, filled into a cup and cooled to room temperature.
[0019] 実施例 2 (イソソルビド +寒天) [0019] Example 2 (isosorbide + agar)
水約 60mLに寒天 1.2gを加えて、 90〜100°Cで数分間加熱撹拌溶解した。次にイソ ソルビド 140gを少量ずつ加えて溶力し均一に混合した後、カップに充填して常温まで 冷却した。 1.2 g of agar was added to about 60 mL of water, and dissolved under heating and stirring at 90 to 100 ° C. for several minutes. Next, 140 g of isosorbide was added little by little, and the mixture was melted and mixed uniformly. Then, the cup was filled and cooled to room temperature.
[0020] 実施例 3「イソソルビド + (寒天 +カラギーナン) +添加剤] [0020] Example 3 "isosorbide + (agar + carrageenan) + additive"
水約 60mLに寒天 1.2g、カラギーナン 0.6g、リン酸水素二カリウム 0.6g、リン酸二水素 カリウム 0.1g、塩化カリウム 0.03g及びサッカリンナトリウム 0.6gをカ卩えて、 90〜100°Cで 数分間加熱撹拌溶解した。次にイソソルビド 140gを少量ずつ加えて溶かし、更に力力 ォ末 0.4g及びチョコレートフレーバー 0.2gをカ卩えて均一に混合し、カップに充填して 常温まで冷却した。 Approximately 60mL of water, 1.2g of agar, 0.6g of carrageenan, 0.6g of dipotassium hydrogen phosphate, dihydrogen phosphate Potassium (0.1 g), potassium chloride (0.03 g) and sodium saccharin (0.6 g) were added and dissolved by stirring at 90-100 ° C for several minutes. Next, 140 g of isosorbide was added and dissolved little by little, and 0.4 g of power and 0.2 g of chocolate flavor were added and mixed uniformly, filled into a cup, and cooled to room temperature.
[0021] 実施例 4「イソソルビド + (寒天 +キサンタンガム) +添加剤] [0021] Example 4 "isosorbide + (agar + xanthan gum) + additive"
水約 60mLに寒天 1.2g、キサンタンガム 0.3g、リン酸水素二カリウム 0.6g、リン酸二水 素カリウム 0.1g、塩化カリウム 0.03g及びサッカリンナトリウム 0.6gをカ卩えて、 90〜100°C で数分間加熱撹拌溶解した。次にイソソルビド 140gを少量ずつ加えて溶かし、更に力 カオ末 0.4g及びチョコレートフレーバー 0.2gを加えて均一に混合し、カップに充填し て常温まで冷却した。 About 60 mL of water, add 1.2 g of agar, 0.3 g of xanthan gum, 0.6 g of dipotassium hydrogen phosphate, 0.1 g of potassium dihydrogen phosphate, 0.03 g of potassium chloride, and 0.6 g of sodium saccharin, and heat at 90-100 ° C for several minutes. Dissolve with heating and stirring. Next, 140 g of isosorbide was added and dissolved little by little. Further, 0.4 g of strength powder and 0.2 g of chocolate flavor were added and mixed uniformly, filled into a cup, and cooled to room temperature.
[0022] 実施例 5「イソソルビド + (寒天 +アルギン酸ナトリウム) +添加剤] [0022] Example 5 "isosorbide + (agar + sodium alginate) + additive"
水約 60mLに寒天 1.2g、アルギン酸ナトリウム 0.3g、リン酸水素二カリウム 0.6g、リン酸 二水素カリウム 0.1g、塩化カリウム 0.03g及びサッカリンナトリウム 0.6gをカ卩えて、 90〜1 00°Cで数分間加熱撹拌溶解した。次にイソソルビド 140gを少量ずつ加えて溶かし、 更にカカオ末 0.4g及びチョコレートフレーバー 0.2gをカ卩えて均一に混合し、カップに 充填して常温まで冷却した。 About 60 mL of water, add 1.2 g of agar, 0.3 g of sodium alginate, 0.6 g of dipotassium hydrogen phosphate, 0.1 g of potassium dihydrogen phosphate, 0.03 g of potassium chloride and 0.6 g of sodium saccharin and count at 90 to 100 ° C. Dissolve with heating and stirring for minutes. Next, 140 g of isosorbide was added little by little, and 0.4 g of cacao powder and 0.2 g of chocolate flavor were added and mixed uniformly, filled into a cup and cooled to room temperature.
[0023] 実施例 6 (寒天量の増減) [0023] Example 6 (Increase / decrease in the amount of agar)
水約 60mLに寒天 0.6g、クェン酸 0.24g、無水リン酸水素ニナトリウム 0.48g及びサッ カリンナトリウム 0.6gを加えて、 90〜100°Cで数分間加熱撹拌溶解した。次にイソソル ビド 140gを少量ずつ加えて溶かし、更にカカオ末 0.4g及びチョコレートフレーバー 0.2 gをカ卩えて均一に混合し、カップに充填して常温まで冷却した。 0.6 g of agar, 0.24 g of citrate, 0.48 g of anhydrous sodium hydrogen phosphate and 0.6 g of saccharin sodium were added to about 60 mL of water, and the mixture was heated and dissolved at 90-100 ° C for several minutes with stirring. Next, 140 g of isosorbide was added and dissolved little by little, and 0.4 g of cacao powder and 0.2 g of chocolate flavor were added and mixed uniformly, filled into a cup and cooled to room temperature.
[0024] 直 (寒天量の増減) [0024] Nao (Increase / decrease in agar amount)
水約 60mLに寒天 3g、クェン酸 0.24g、無水リン酸水素ニナトリウム 0.48g及びサッカリ ンナトリウム 0.6gをカ卩えて、 90〜100°Cで数分間加熱撹拌溶解した。次にイソソルビド 1 40gを少量ずつ加えて溶かし、更にカカオ末 0.4g及びチョコレートフレーバー 0.2gを 加えて均一に混合し、カップに充填して常温まで冷却した。 Approximately 60 mL of water was charged with 3 g of agar, 0.24 g of citrate, 0.48 g of anhydrous sodium hydrogenphosphate and 0.6 g of sodium saccharin, and dissolved by stirring at 90-100 ° C for several minutes. Next, 40 g of isosorbide 140 was added and dissolved little by little, and 0.4 g of cacao powder and 0.2 g of chocolate flavor were added and mixed uniformly, filled into a cup, and cooled to room temperature.
[0025] 皇 (寒天量の増減) [0025] Emperor (change in agar)
水約 60mLに寒天 7g、クェン酸 0.24g、無水リン酸水素ニナトリウム 0.48g及びサッカリ ンナトリウム 0.6gをカ卩えて、 90〜100°Cで数分間加熱撹拌溶解した。次にイソソルビド 1 40gを少量ずつ加えて溶かし、更にカカオ末 0.4g及びチョコレートフレーバー 0.2gを 加えて均一に混合し、カップに充填して常温まで冷却した。 About 60 mL of water, 7 g of agar, 0.24 g of citrate, 0.48 g of anhydrous sodium hydrogen phosphate and saccharide 0.6 g of sodium carbonate was added and dissolved by stirring at 90-100 ° C for several minutes. Next, 40 g of isosorbide 140 was added and dissolved little by little, and 0.4 g of cacao powder and 0.2 g of chocolate flavor were added and mixed uniformly, filled into a cup, and cooled to room temperature.
[0026] 対照例 1 (液剤) [0026] Control 1 (Liquid)
イソソルビド 70gに水 30mLをカ卩えて溶かした。 30 mL of water was dissolved in 70 g of isosorbide and dissolved.
[0027] 対照例 2 (イソソルビド +ぺクチン +添加剤) [0027] Control Example 2 (isosorbide + pectin + additive)
水約 55mLにぺクチン lg、クェン酸 4.8g及びサッカリンナトリウム 0.6gをカ卩えて、 90〜1 00°Cで数分間加熱撹拌溶解した。次にイソソルビド 140gを少量ずつ加えて溶かし、 更にカカオ末 0.4g及びチョコレートフレーバー 0.2gをカ卩えて均一に混合し、カップに 充填して常温まで冷却した。 In about 55 mL of water, pectin lg, 4.8 g of citrate and 0.6 g of saccharin sodium were added and dissolved by stirring at 90 to 100 ° C. for several minutes. Next, 140 g of isosorbide was added little by little, and 0.4 g of cacao powder and 0.2 g of chocolate flavor were added and mixed uniformly, filled into a cup and cooled to room temperature.
[0028] 針照例 3 (イソソノレビド +ローカストビーンガム +キサンタンガム) [0028] Needle illumination example 3 (Isosonolevid + locust bean gum + xanthan gum)
水約 60mLにローカストビーンガム 0.56g、キサンタンガム 0.56g、リン酸水素二力リウ ム 0.3g及びサッカリンナトリウム 0.6gをカ卩えて、 90〜100°Cで数分間加熱撹拌溶解した 。次にイソソルビド 140gを少量ずつ加えて溶かし、更にカカオ末 0.4g及びチョコレート フレーバー 0.2gをカ卩えて均一に混合し、カップに充填して常温まで冷却した。 In about 60 mL of water, 0.56 g of locust bean gum, 0.56 g of xanthan gum, 0.3 g of bibasic hydrogen phosphate and 0.6 g of sodium saccharin were added and dissolved by stirring at 90-100 ° C. for several minutes. Next, 140 g of isosorbide was added and dissolved little by little, and 0.4 g of cacao powder and 0.2 g of chocolate flavor were added and mixed uniformly, filled into a cup and cooled to room temperature.
[0029] 針照例 4 (イソソノレビド +ダルコマンナン +キサンタンガム) [0029] Needle illumination example 4 (Isosonolevid + Darcomannan + Xanthan gum)
水約 60mLにダルコマンナン 0.5g、キサンタンガム 0.5g及びサッカリンナトリウム 0.6g を加えて、 90〜100°Cで数分間加熱撹拌溶解した。次にイソソルビド 140gを少量ずつ 加えて溶かし、更にカカオ末 0.4g及びチョコレートフレーバー 0.2gをカ卩えて均一に混 合し、カップに充填して常温まで冷却した。 To about 60 mL of water, 0.5 g of dalcomannan, 0.5 g of xanthan gum and 0.6 g of saccharin sodium were added, and dissolved by stirring with heating at 90 to 100 ° C. for several minutes. Next, 140 g of isosorbide was added little by little to dissolve, and 0.4 g of cacao powder and 0.2 g of chocolate flavor were mixed and mixed uniformly, filled into a cup and cooled to room temperature.
[0030] 対照例 5 (イソソノレビド +ローカストビーンガム +キサンタンガム) [0030] Control Example 5 (Isosonolevid + locust bean gum + xanthan gum)
水約 55mLにローカストビーンガム 1.4g、キサンタンガム 1.4g、クェン酸 0.24g、無水リ ン酸水素ニナトリウム 0.48g及びサッカリンナトリウム 0.6gをカ卩えて、 90〜100°Cで数分 間加熱撹拌溶解した。次にイソソルビド 140gを少量ずつ加えて溶かし、更にカカオ末 0.4g及びチョコレートフレーバー 0.2gを加えて均一に混合し、カップに充填して常温 まで冷却した。 Locust bean gum (1.4 g), xanthan gum (1.4 g), citrate (0.24 g), anhydrous sodium hydrogenphosphate (0.48 g) and saccharin sodium (0.6 g) were added to about 55 mL of water, and dissolved by stirring at 90-100 ° C for several minutes. . Next, 140 g of isosorbide was added little by little to dissolve, and 0.4 g of cacao powder and 0.2 g of chocolate flavor were added and mixed uniformly, filled into a cup and cooled to room temperature.
[0031] 対照例 6 (イソソノレビド +ジエランガム) [0031] Control Example 6 (Isosonolevid + dielan gum)
水約 60mLにジエランガム 0.9g、リン酸水素二カリウム 0.6g、クェン酸ナトリウム lg及び サッカリンナトリウム 0.6gをカ卩えて、 90〜100°Cで数分間加熱撹拌溶解した。次にイソ ソルビド 140gを少量ずつ加えて溶かし、更にカカオ末 0.4g及びチョコレートフレーバ 一 0.2gをカ卩えて均一に混合し、カップに充填して常温まで冷却した。 About 60 mL of water, 0.9 g of dielan gum, 0.6 g of dipotassium hydrogen phosphate, sodium citrate lg and 0.6 g of saccharin sodium was added and dissolved by stirring at 90-100 ° C for several minutes. Next, 140 g of isosorbide was added and dissolved little by little. Further, 0.4 g of cacao powder and 0.2 g of chocolate flavor were mixed and mixed uniformly, filled into a cup, and cooled to room temperature.
[0032] [試験例 1] (官能試験) [0032] [Test Example 1] (Sensory test)
5名の被験者により、実施例 実施例 2及び対照例 1の服用感を評価した。ここで は、被験者はゼリー製剤約 5gを口中に入れ、数回咀嚼して評価した。また、液剤はそ の約 5gを口の中に入れて評価した。評価は、苦みを感じない場合を 1とし非常に強い 苦みがあり服用し難いを 5とする 5段階の評価により行った。その試験結果を表 1に示 す。 The feeling of administration of Example Example 2 and Control Example 1 was evaluated by five subjects. Here, the subject put about 5 g of jelly preparation in his mouth and chewed several times for evaluation. In addition, about 5g of the liquid was put in the mouth and evaluated. The evaluation was based on a five-step evaluation, with 1 being no bitterness and 5 being very bitter and difficult to take. The test results are shown in Table 1.
[0033] [表 1] [0033] [Table 1]
【表 1】 【table 1】
[0034] イソソルビド及び寒天力もなるゼリー製剤は、イソソルビド液の服用感を改善した。 [0034] The jelly preparation that also has isosorbide and agar power improved the feeling of taking isosorbide solution.
通常、カカオ末は、苦み物質に対して数十 %力も数百%添加しないと効果を発揮しな いが、実施例 1においては、苦味物質であるイソソルビドが 70%の高濃度で含まれてい るにも関わらず、寒天とカカオ末との相乗効果により、少量のカカオ末で優れた苦味 低減効果を示すことが確認された。 Normally, cacao powder will not be effective unless several tens of percent or even hundreds of percent of the bitter substance is added, but in Example 1, isosorbide, a bitter substance, is contained at a high concentration of 70%. In spite of this, it was confirmed that a small amount of cacao powder showed an excellent bitterness reduction effect due to the synergistic effect of agar and cacao powder.
[0035] [試験例 2] (官能試験及びゲルの硬さ;寒天量の影響) [Test Example 2] (Sensory test and gel hardness; influence of agar amount)
6名の被験者により、実施例 実施例 6、実施例 7及び実施例 8のゼリー製剤の服 用感を比較し、添加する寒天量の影響を検討した。被検者は、ゼリー製剤約 5gを口 中に入れ数回咀嚼して評価した。苦みの評価につ ヽては 、ずれのゼリー製剤も苦み が低減されているため、評価基準を設定することが困難であったため、相対評価とし て苦みが少ない順に順位づけした。また、総合的服用し易さは非常に服用しやすい を 1、服用し難いを 5とする 5段階評価により行った。また、ゼリーの硬さは、レオメータ 一を用いて一定面積のプランジャーを用い、ゼリーを 60mm/minの速度で圧縮して、 ゼリーが破断するときの強度を測定した。その試験結果を表 2、表 3及び図 1に示す。 Six subjects compared the feeling of administration of the jelly preparations of Example 6, Example 7, and Example 8, and examined the effect of the amount of agar added. The subjects put about 5 g of jelly preparation into their mouth and chewed several times for evaluation. Regarding the evaluation of bitterness, since the bitterness of the miscellaneous jelly preparations has also been reduced, it was difficult to set an evaluation standard. Ranking in ascending order of bitterness. In addition, the overall ease of taking was evaluated based on a five-step evaluation, with 1 being very easy to take and 5 being difficult to take. The hardness of the jelly was measured by compressing the jelly at a rate of 60 mm / min using a rheometer with a fixed area plunger and measuring the strength when the jelly breaks. The test results are shown in Table 2, Table 3, and Figure 1.
[表 2] [Table 2]
【表 2】 [Table 2]
相 対 評 価 Relative evaluation
[0037] [表 3] [0037] [Table 3]
【表 3】 [Table 3]
総合的服用し易さ Total ease of taking
[0038] 実施例 6は相対的に苦味を低減する効果が少な力つた。その原因はこのゲルはや わら力べて口の中で崩れやすぐ寒天とカカオ末の相乗効果が少な力つたためと考え られた。逆に寒天の添加量が多い実施例 8のゲルは図 1に示すように非常に固ぐァ ンケート結果より、苦味の低減効果は十分に確認されたものの服用感が非常に悪か つた。また、製造時の粘度が非常に高ぐ大量生産することは不可能であると考えら れた。従って寒天の添カ卩量としては 0.3〜2w/w%が好ましぐ更に 0.5〜1.5 w/w%がより 好ましいと考えられる。 [0038] Example 6 was relatively less effective in reducing bitterness. The reason for this was thought to be that the gel collapsed in the mouth and the synergistic effect between the agar and cacao powder was weak. Conversely, the gel of Example 8 with a large amount of agar added is very hard as shown in FIG. From the questionnaire results, although the bitterness reduction effect was sufficiently confirmed, the feeling of taking was very bad. In addition, it was considered impossible to mass-produce with very high viscosity during production. Therefore, it is considered that 0.3-2 w / w% is preferred as the amount of the agar supplement, and more preferably 0.5-1.5 w / w%.
[0039] [試験例 3] (溶出試験;他のゲル化剤との比較) [0039] [Test Example 3] (Dissolution test; comparison with other gelling agents)
実施例 1及び対照例 2〜対照例 6より得られたゼリー製剤力ものイソソルビドの溶出 性を、 日本薬局方溶出試験法パドル法にて試験した。ただし、試験液には、水、 日 本薬局方崩壊試験法第 1液及び第 2液 900mLを用いて、パドル回転数は 50rpmとし た。また、ゼリー製剤は、咀嚼を考慮して約 2mm径の大きさに粉砕して投入した。な お、定量は HPLC法により行った。寒天を用いたゼリー製剤と他のゲル化剤を用いて 作製したゼリー製剤力ものイソソルビドの溶出性の比較を図 2〜図 4に、また、図 5には 実施例 1及び各対照例の 15分後の溶出率をまとめて示した。 The elution properties of isosorbide having the jelly preparation strength obtained from Example 1 and Control Example 2 to Control Example 6 were tested by the Japanese Pharmacopoeia dissolution test method paddle method. However, water, 900 mL of the Japanese Pharmacopoeia Disintegration Test Method 1 and 2 were used as the test solution, and the paddle rotation speed was 50 rpm. The jelly preparation was pulverized into a size of about 2 mm in consideration of mastication. The quantification was performed by the HPLC method. A comparison of the dissolution properties of isosorbide with jelly preparations prepared using a jelly preparation using agar and other gelling agents is shown in Figs. 2 to 4, and Fig. 5 shows the results of Example 1 and each control example. The elution rate after minutes was shown together.
[0040] ゲル化剤として寒天を用いたゼリー製剤である実施例 1のみ力 水、第 1液及び第 2 液の 、ずれの試験液にぉ 、てもイソソルビドの速やかな溶出を示し、生体内の環境 に依存しない速やかな溶出を示すことがわ力つた。尚、各対照例に使用される各ゲ ル化剤の添加量は一般的に用いられる量であり、対照例で得られたゼリー製剤の硬 さは実施例 1と同等か又は柔らかいため、本試験は、対照例に不利な条件での比較 ではない。 [0040] Only in Example 1, which is a jelly preparation using agar as a gelling agent, even if the test solution of water, the first solution, and the second solution is misaligned, isosorbide is rapidly dissolved, It was remarkable that it showed rapid elution independent of the environment. The amount of each gelling agent used in each control example is a commonly used amount, and the hardness of the jelly preparation obtained in the control example is the same as or softer than that in Example 1. The test is not a comparison under conditions unfavorable to the control.
[0041] [試験例 4] (溶出試験;カカオ末等の影響) [0041] [Test Example 4] (Elution test; influence of cacao powder, etc.)
実施例 1及び実施例 2のゼリー製剤からのイソソルビドの溶出性試験を、試験例 3と 同様の方法により行った。試験結果の代表例を図 6に示す。カカオ末及びその他の 添加剤は、寒天を用いたゼリー製剤力ものイソソルビドの溶出に影響せず、実施例 1 , 2ともに、イソソルビドはゼリー製剤力も速やかに溶出した。なお、その他のゲル化剤 を用いて作製したゼリー製剤に関しても、カカオ末及びその他の添加剤はイソソルビ ドの溶出に影響しな力つた。 The dissolution test of isosorbide from the jelly preparations of Example 1 and Example 2 was performed in the same manner as in Test Example 3. Figure 6 shows a typical example of the test results. The cacao powder and other additives did not affect the elution of isosorbide with jelly preparation ability using agar, and in both Examples 1 and 2, isosorbide quickly eluted with jelly preparation ability. Regarding jelly preparations prepared using other gelling agents, cocoa powder and other additives did not affect the elution of isosorbide.
[0042] [試験例 5] (溶出試験;寒天量の影響) [0042] [Test Example 5] (Dissolution test; influence of agar amount)
実施例 1及び実施例 6〜実施例 8のゼリー製剤からのイソソルビドの溶出性試験を、 試験例 3と同様の方法により行った。試験結果を図 7〜図 9に示す。ゼリー製剤からの イソソルビドの溶出は寒天の添加量により大きくは影響されないが、添加量が極めて 多 、と若干溶出の遅延を示した。 The dissolution test of isosorbide from the jelly preparations of Example 1 and Examples 6 to 8 was performed in the same manner as in Test Example 3. The test results are shown in Figs. From jelly preparations The elution of isosorbide was not greatly affected by the amount of agar added, but the amount added was very large, indicating a slight delay in elution.
[0043] [試験例 6] (溶出試験;混合ゲル化系) [0043] [Test Example 6] (Dissolution test; mixed gelation system)
実施例 実施例 3〜実施例 5のゼリー製剤からのイソソルビドの溶出性試験を、試 験例 5と同様の方法により行った。試験結果を図 10〜図 12に示す。ゲル化剤として寒 天を用いたイソソルビド含有ゼリー製剤にぉ ヽては、更にその他のゲル化剤を添加し ても、イソソルビドの速やかな溶出特性を維持して ヽた。 Examples The dissolution test of isosorbide from the jelly preparations of Examples 3 to 5 was performed in the same manner as in Test Example 5. The test results are shown in Figs. In the case of an isosorbide-containing jelly preparation using agar as the gelling agent, the rapid dissolution characteristics of isosorbide were maintained even when other gelling agents were added.
図面の簡単な説明 Brief Description of Drawings
[0044] [図 1]イソソルビド含有ゼリー製剤の硬さと寒天の添加量の関係を示す図である。 FIG. 1 is a graph showing the relationship between the hardness of an isosorbide-containing jelly preparation and the amount of agar added.
[図 2]イソソルビド含有ゼリー製剤の「日局」崩壊試験法第 1液 (pHl.2)への溶出試験 結果を示す図である。 FIG. 2 is a graph showing the results of an elution test of an isosorbide-containing jelly preparation into the “JP” disintegration test method solution 1 (pH 1).
[図 3]イソソルビド含有ゼリー製剤の水への溶出試験結果を示す図である。 FIG. 3 is a graph showing the results of a dissolution test for isosorbide-containing jelly preparations in water.
[図 4]イソソルビド含有ゼリー製剤の「日局」崩壊試験法第 2液 (pH6.8)への溶出試験 結果を示す図である。 FIG. 4 is a graph showing the results of an elution test of an isosorbide-containing jelly preparation into the second solution (pH 6.8) of “JP” disintegration test method.
[図 5]イソソルビド含有ゼリー製剤の各溶出試験液への 15分後の溶出率を示す図で ある。 FIG. 5 is a graph showing the dissolution rate of an isosorbide-containing jelly preparation after 15 minutes in each dissolution test solution.
[図 6]イソソルビド含有ゼリー製剤の溶出性に及ぼすカカオ末添加の影響を示す図で ある。 FIG. 6 is a graph showing the effect of adding cacao powder on the dissolution properties of isosorbide-containing jelly preparations.
[図 7]イソソルビド含有ゼリー製剤の「日局」崩壊試験法第 1液 (pHl.2)への溶出性に 及ぼす寒天添加量の影響を示す図である。 FIG. 7 is a graph showing the effect of the amount of agar added on the dissolution properties of an isosorbide-containing jelly preparation into the “JP” disintegration test method solution 1 (pH 1).
[図 8]イソソルビド含有ゼリー製剤の水への溶出性に及ぼす寒天添加量の影響を示 す図である。 FIG. 8 is a graph showing the effect of the amount of agar added on the dissolution property of isosorbide-containing jelly preparations in water.
[図 9]イソソルビド含有ゼリー製剤の「日局」崩壊試験法第 2液 (pH6.8)への溶出性に 及ぼす寒天添加量の影響を示す図である。 FIG. 9 is a graph showing the effect of the amount of agar added on the dissolution properties of isosorbide-containing jelly preparations into the “JP” disintegration test method solution 2 (pH 6.8).
[図 10]イソソルビド含有ゼリー製剤の「日局」崩壊試験法第 1液 (pHl.2)への溶出性に 及ぼすその他のゲル化剤添加の影響を示す図である。 FIG. 10 is a graph showing the effect of addition of other gelling agents on the dissolution properties of isosorbide-containing jelly preparations into the “JPA” disintegration test method solution 1 (pH 1).
[図 11]イソソルビド含有ゼリー製剤の水への溶出性に及ぼすその他のゲル化剤添カロ の影響を示す図である。 圆 12]イソソルビド含有ゼリー製剤の「日局」崩壊試験法第 2液 (PH6.8)への溶出性に 及ぼすその他のゲル化剤添加の影響を示す図である。 FIG. 11 is a graph showing the influence of other gelling agent-added calories on the solubility of isosorbide-containing jelly preparations in water. [12] This is a graph showing the effect of addition of other gelling agents on the dissolution properties of jelly preparations containing isosorbide into the “JPA” disintegration test method solution 2 ( PH 6.8).
Claims
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006528598A JP4264105B2 (en) | 2004-06-24 | 2005-06-23 | Isosorbide-containing jelly preparation |
| CN2005800117601A CN1942183B (en) | 2004-06-24 | 2005-06-23 | Gel formulations containing isosorbide |
| KR1020067025712A KR101175163B1 (en) | 2004-06-24 | 2005-06-23 | Isosorbide-containing jelly preparation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004185960 | 2004-06-24 | ||
| JP2004-185960 | 2004-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006001344A1 true WO2006001344A1 (en) | 2006-01-05 |
Family
ID=35781797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2005/011555 Ceased WO2006001344A1 (en) | 2004-06-24 | 2005-06-23 | Isosorbide-containing jelly preparation |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP4264105B2 (en) |
| KR (1) | KR101175163B1 (en) |
| CN (1) | CN1942183B (en) |
| WO (1) | WO2006001344A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006193514A (en) * | 2004-12-15 | 2006-07-27 | Aska Pharmaceutical Co Ltd | Oral preparation with reduced bitter taste of isosorbide and method for producing the same |
| JP2007254340A (en) * | 2006-03-22 | 2007-10-04 | Lintec Corp | Oral medicine |
| WO2008084533A1 (en) * | 2007-01-10 | 2008-07-17 | Kowa Co., Ltd. | Therapeutic agent for meniere’s disease |
| WO2010150400A1 (en) * | 2009-06-26 | 2010-12-29 | 日医工株式会社 | Jelly preparation containing isosorbide |
| JP2012107060A (en) * | 2004-12-15 | 2012-06-07 | Aska Pharmaceutical Co Ltd | Oral formulation in which bitter taste of isosorbide was alleviated, method for producing the same |
| CN102552310A (en) * | 2007-01-10 | 2012-07-11 | 兴和株式会社 | Meniere disease curative |
| WO2012099082A1 (en) * | 2011-01-17 | 2012-07-26 | 味の素株式会社 | Branched-chain amino acid-containing jelly |
| FR3101546A1 (en) * | 2019-10-07 | 2021-04-09 | Roquette Freres | Masking the taste of isosorbide |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2861301T3 (en) | 2007-06-13 | 2021-10-06 | Otsuka Pharma Co Ltd | Gelatin and drink containing equol |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04346937A (en) * | 1991-05-24 | 1992-12-02 | Kibun Foods Inc | Bitterness reduction method |
| JP2000095710A (en) * | 1998-09-21 | 2000-04-04 | Taisho Pharmaceut Co Ltd | Oral solid preparation containing cocoa powder |
| JP2001226293A (en) * | 2000-02-17 | 2001-08-21 | Kotaro Kanpo Seiyaku Kk | Dosage aid |
-
2005
- 2005-06-23 JP JP2006528598A patent/JP4264105B2/en not_active Expired - Lifetime
- 2005-06-23 KR KR1020067025712A patent/KR101175163B1/en not_active Expired - Fee Related
- 2005-06-23 CN CN2005800117601A patent/CN1942183B/en not_active Expired - Fee Related
- 2005-06-23 WO PCT/JP2005/011555 patent/WO2006001344A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04346937A (en) * | 1991-05-24 | 1992-12-02 | Kibun Foods Inc | Bitterness reduction method |
| JP2000095710A (en) * | 1998-09-21 | 2000-04-04 | Taisho Pharmaceut Co Ltd | Oral solid preparation containing cocoa powder |
| JP2001226293A (en) * | 2000-02-17 | 2001-08-21 | Kotaro Kanpo Seiyaku Kk | Dosage aid |
Non-Patent Citations (1)
| Title |
|---|
| Edited by Zaidan Hojin Nippon Iyaku Joho Senta, Iryoyaku Nippon Iyakuhinshu, Yakuji Jihosha, 25 october, 2000 (25.10.00), page 211 * |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012107060A (en) * | 2004-12-15 | 2012-06-07 | Aska Pharmaceutical Co Ltd | Oral formulation in which bitter taste of isosorbide was alleviated, method for producing the same |
| JP2006193514A (en) * | 2004-12-15 | 2006-07-27 | Aska Pharmaceutical Co Ltd | Oral preparation with reduced bitter taste of isosorbide and method for producing the same |
| JP2007254340A (en) * | 2006-03-22 | 2007-10-04 | Lintec Corp | Oral medicine |
| KR101406231B1 (en) * | 2007-01-10 | 2014-06-12 | 세츠코 다케다 | Therapeutic agent for meniere's disease |
| WO2008084533A1 (en) * | 2007-01-10 | 2008-07-17 | Kowa Co., Ltd. | Therapeutic agent for meniere’s disease |
| CN102552310A (en) * | 2007-01-10 | 2012-07-11 | 兴和株式会社 | Meniere disease curative |
| US8445461B2 (en) | 2007-01-10 | 2013-05-21 | Setsuko Takeda | Pharmaceutical composition for meniere's disease |
| WO2010150400A1 (en) * | 2009-06-26 | 2010-12-29 | 日医工株式会社 | Jelly preparation containing isosorbide |
| WO2012099082A1 (en) * | 2011-01-17 | 2012-07-26 | 味の素株式会社 | Branched-chain amino acid-containing jelly |
| JPWO2012099082A1 (en) * | 2011-01-17 | 2014-06-30 | 味の素株式会社 | Jelly containing branched chain amino acids |
| JP2017036329A (en) * | 2011-01-17 | 2017-02-16 | Eaファーマ株式会社 | Jelly containing branched chain amino acids |
| JP6093181B2 (en) * | 2011-01-17 | 2017-03-08 | Eaファーマ株式会社 | Jelly containing branched chain amino acids |
| FR3101546A1 (en) * | 2019-10-07 | 2021-04-09 | Roquette Freres | Masking the taste of isosorbide |
| WO2021069836A1 (en) | 2019-10-07 | 2021-04-15 | Roquette Freres | Masking the taste of isosorbide |
| JP2022550858A (en) * | 2019-10-07 | 2022-12-05 | ロケット フレール | isosorbide taste masking |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101175163B1 (en) | 2012-08-20 |
| KR20070023719A (en) | 2007-02-28 |
| CN1942183A (en) | 2007-04-04 |
| JPWO2006001344A1 (en) | 2008-04-17 |
| JP4264105B2 (en) | 2009-05-13 |
| CN1942183B (en) | 2011-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8287897B2 (en) | Bitterness-masking particulate jelly beverage | |
| EP3641774B1 (en) | Pectin gummy composition and methods of making and using thereof | |
| JP5249941B2 (en) | Granular jelly drink for medicine and method for producing the same | |
| JP3257983B2 (en) | Drug swallowing aid drink | |
| JP6263699B2 (en) | Aqueous drug delivery system with an unpleasant taste masking agent | |
| JP2001226293A (en) | Dosage aid | |
| JP4941977B2 (en) | Oral jelly-like pharmaceutical composition of benzisoxazole derivative | |
| JP4264105B2 (en) | Isosorbide-containing jelly preparation | |
| JP2009256216A (en) | Liquid amlodipine besylate formulation for internal administration stable in solution state | |
| JP2006052169A (en) | Sol-like or gel-like administration assistant food | |
| JP5611672B2 (en) | Oral jelly | |
| CN111511222B (en) | Composition for calcium supplementation | |
| EP3678498B1 (en) | Composition for calcium supplementation | |
| JPH11322606A (en) | Readily swallowable anti-malignant tumor preparation | |
| KR101486534B1 (en) | Oral preparation and preparation method of the same | |
| JP2010265248A (en) | Jelly formulation | |
| HK40022725B (en) | Composition for calcium supplementation | |
| HK40022725A (en) | Composition for calcium supplementation | |
| JP2005139173A (en) | Jelly pharmaceutical preparation containing biguanide-based medicine | |
| HK1087916A (en) | Bitterness-masking particulate jelly beverage | |
| JP2014009211A (en) | Sol pharmaceutical composition containing itraconazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2006528598 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 200580011760.1 Country of ref document: CN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020067025712 Country of ref document: KR |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| WWP | Wipo information: published in national office |
Ref document number: 1020067025712 Country of ref document: KR |
|
| 122 | Ep: pct application non-entry in european phase |